OnKure Therapeutics, Inc. (OKUR)

NASDAQ: OKUR · Real-Time Price · USD
2.000
-0.155 (-7.19%)
May 8, 2025, 4:00 PM EDT - Market closed
-7.19%
Market Cap 26.87M
Revenue (ttm) n/a
Net Income (ttm) -59.06M
Shares Out 13.44M
EPS (ttm) -8.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 98,744
Open 2.100
Previous Close 2.155
Day's Range 1.990 - 2.100
52-Week Range 1.980 - 20.000
Beta n/a
Analysts Strong Buy
Price Target 32.25 (+1,512.5%)
Earnings Date May 6, 2025

About OKUR

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 46
Stock Exchange NASDAQ
Ticker Symbol OKUR
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for OKUR stock is "Strong Buy." The 12-month stock price forecast is $32.25, which is an increase of 1,512.50% from the latest price.

Price Target
$32.25
(1,512.50% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data

2 days ago - GlobeNewsWire

OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

— PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024

2 months ago - GlobeNewsWire

OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences

BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncol...

2 months ago - GlobeNewsWire

OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported

5 months ago - GlobeNewsWire

OnKure Announces New Date for Upcoming Investor Call

Investor call to review preliminary data from the PIKture-01 trial is now planned for Tuesday, December 10th, at 7 a.m. CT Investor call to review preliminary data from the PIKture-01 trial is now pla...

5 months ago - GlobeNewsWire

OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET

6 months ago - GlobeNewsWire

OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond

Initial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the treatment of patients with PI3Ka-H1047R breast cancer and solid tumors, is expected in Q4 of 2024. OKI-2...

7 months ago - Seeking Alpha